ImmunoPrecise Antibodies (NASDAQ:IPA – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Friday, March 28th. Analysts expect ImmunoPrecise Antibodies to post earnings of ($0.06) per share and revenue of $6.59 million for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.
ImmunoPrecise Antibodies Price Performance
IPA stock opened at $0.44 on Wednesday. The company has a market capitalization of $13.67 million, a P/E ratio of -0.56 and a beta of 0.09. ImmunoPrecise Antibodies has a 52-week low of $0.27 and a 52-week high of $1.64. The company has a fifty day moving average price of $0.44 and a 200-day moving average price of $0.48. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.85 and a current ratio of 1.01.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of ImmunoPrecise Antibodies in a research report on Friday, March 14th.
ImmunoPrecise Antibodies Company Profile
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.
Recommended Stories
- Five stocks we like better than ImmunoPrecise Antibodies
- Are Penny Stocks a Good Fit for Your Portfolio?
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- NVIDIA Insiders Sell: This Is What It Means for the Market
- Investing In Preferred Stock vs. Common Stock
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for ImmunoPrecise Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoPrecise Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.
